Crossmark

Comparing rapid micro-induction and standard induction of buprenorphine/naloxone for treatment of opioid use disorder: protocol for an open-label, parallel-group, superiority, randomized controlled trial

Crossref DOI link: https://doi.org/10.1186/s13722-021-00220-2

Published Online: 2021-02-12

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wong, James S. H.

Nikoo, Mohammadali

Westenberg, Jean N.

Suen, Janet G.

Wong, Jennifer Y. C.

Krausz, Reinhard M.

Schütz, Christian G.

Vogel, Marc

Sidhu, Jesse A.

Moe, Jessica

Arishenkoff, Shane

Griesdale, Donald

Mathew, Nickie

Azar, Pouya
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct04234191 at ClinicalTrials.gov

Documents that mention this clinical trial

Comparing rapid micro-induction and standard induction of buprenorphine/naloxone for treatment of opioid use disorder: protocol for an open-label, parallel-group, superiority, randomized controlled trial
https://doi.org/10.1186/s13722-021-00220-2
Funding

Funding for this research was provided by:

VGH and UBC Hospital Foundation

Frederick Banting and Charles Best Canada Graduate Scholarships (157934)
License Information

Text and Data Mining valid from 2021-02-12

Version of Record valid from 2021-02-12
More Information

Article History

Received: 23 July 2020

Accepted: 23 January 2021

First Online: 12 February 2021

Ethics approval and consent to participate

: This study was approved by the Research Ethics Board of the University of British Columbia (H19-03254).

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below